Management of myelofibrosis: JAK inhibition and beyond
Author:
Affiliation:
1. Yale University School of Medicine, Department of Internal Medicine, Section of Hematology and the Yale Cancer Center, New Haven, CT, USA
Publisher
Informa UK Limited
Subject
Hematology
Link
https://www.tandfonline.com/doi/pdf/10.1080/17474086.2017.1317590
Reference139 articles.
1. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
2. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)
3. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors
4. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases
5. Acute Transformation in Nonleukemic Chronic Myeloproliferative Disorders: Actuarial Probability and Main Characteristics in a Series of 218 Patients
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Pelabresib (CPI-0610): An Exciting Novel Drug for the Treatment of Myelofibrosis;Current Hematologic Malignancy Reports;2023-05-17
2. Targeting BET Bromodomains in Cancer;Annual Review of Cancer Biology;2022-04-11
3. Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 – 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study;Clinical Lymphoma Myeloma and Leukemia;2021-11
4. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure;American Journal of Hematology;2020-04-17
5. Chronic Myeloproliferative Neoplasms (Other Than Chronic Myeloid Leukemia);Practical Lymph Node and Bone Marrow Pathology;2020
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3